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ORIGINAL ARTICLEInitial Staging of Locally Advanced Rectal Cancer
and Regional Lymph Nodes
Comparison of Diffusion-Weighted MRI With 18F-FDG-PET/CTMilena Cerny, MD,* Vincent Dunet, MD,* John Olivier Prior, PhD, MD,† Dieter Hahnloser, MD,‡
Anna Dorothea Wagner, MD,§ Reto Antoine Meuli, MD,* and Sabine Schmidt, MD*Purpose: The aim of the study was to compare diffusion-weighted MRI
(DW-MRI) parameters with 18F-FDG PET/CT in primary locally advanced
rectal cancer (LARC).
Methods: From October 2012 to September 2014, 24 patients with histo-
logically confirmed and untreated LARC (T3–T4) prospectively underwent
a pelvic 1.5-T DW-MRI (b = 0 s/mm2, b = 600 s/mm2) and a whole-body
18F-FDG PET/CT, before neoadjuvant therapy. The 2 examinations were
performed on the same day. Two readers measured 18F-FDG SUVmax and
SUVmean of the rectal tumor and of the pathological regional lymph nodes
on PET/CTand compared thesewithminimum andmeanvalues of the ADC
(ADCmin and ADCmean) on maps generated from DW-MRI. The diag-
nostic performance of ADC values in identifying pathological lymph
nodes was also assessed.
Results: Regarding tumors (n = 24), we found a significant negative corre-
lation between SUVmean and corresponding ADCmean values (ρ = −0.61,
P = 0.0017) and between ADCmin and SUVmax (ρ = −0.66, P = 0.0005).
Regarding the lymph nodes (n = 63), there was a significant negative corre-
lation between ADCmean and SUVmean values (ρ = −0.38, P = 0.0021),
but not between ADCmin and SUVmax values (ρ = −0.11, P = 0.41). Nei-
ther ADCmean nor ADCmin values helped distinguish pathological from
benign lymph nodes (AUC of 0.24 [confidence interval, 0.10–0.38] and
0.41 [confidence interval, 0.22–0.60], respectively).
Conclusions: The correlations between ADCmean and SUVmean sug-
gest an association between tumor cellularity and metabolic activity in
untreated LARC and in regional lymph nodes. However, compared with
18F-FDG PET/CT, ADC values are not reliable for identifying patholog-
ical lymph nodes.
Key Words: 18F-FDG SUV, ADC, locally advanced rectal cancer,
lymph nodes, MRI, PET/CT
(Clin Nucl Med 2016;41: 289–295)
C olorectal cancer is the second most common cancer, with447,000 new cases per year in 2012, and the third most common
cause of death from cancer in Europe. Rectal carcinoma represents
40% to 50% of colorectal cancers, among them 95% being adenocar-
cinoma.1 Risk of local recurrence is substantial and correlates toReceived for publication September 3, 2015; revision accepted January 5, 2016.
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Clinical Nuclear Medicine • Volume 41, Number 4, April 2016the extension and grade of the tumor and to the nodal status at initial
presentation.2
Pelvic MRI and 18F-FDG PET/CT are useful for staging and
therapeutic management. Pelvic MRI allows for accurate definition
of the distance to mesorectal fascia,3,4 which is a predictor of the
local recurrence rate, as well as for definition of the regional nodal
status. Although not commonly used in daily practice,5 18F-FDG
PET/CTalso helps in evaluating the nodal status and is especially
performed for the detection of distant metastases.6 MRI and
18F-FDG PET/CT are thus 2 complementary modalities for the ini-
tial staging of advanced rectal cancer. 18F-FDG PET/CT provides
the SUV, a quantitative measure of the metabolic activity of tumoral
tissues that correlates with the tumor proliferative rate,7 whereas
diffusion-weighted imaging (DWI) with ADC provides a quantita-
tive measure of water diffusion in tissue that correlates with the
tumor cell density and the histological differentiation grade.8 The
relation between quantitative parameters of 18F-FDG PET/CT and
DWI has been assessed for various tumors and suggests a correla-
tion between tumor metabolic activity and cellularity.9,10 However,
only a few studies have assessed this relation in locally advanced
rectal cancer (LARC).11,12
The purposes of our study were to assess the relation be-
tween ADC and SUV for the primary tumor and the regional lymph
nodes in LARC before neoadjuvant treatment and to assess the di-
agnostic performance of ADC values in identifying pathological
lymph nodes.
MATERIALS AND METHODS
Population
From October 2012 to September 2014, 27 consecutive pa-
tients were prospectively enrolled in our study (19 men, 8 women;
mean age, 63 ± 12 years [range, 45–87 years]). Inclusion criteria
were a locally advanced, biopsy-proven rectal cancer (T3 and
T4 stage) based on endorectal US (ERUS) and colonoscopic find-
ings and no previous treatment of this tumor. Exclusion criteriawere
T1 and T2 stage rectal cancer revealed by imaging (ERUS and/or
MRI), known contraindications to MRI, and incomplete baseline
examinations. All patients underwent both baseline pelvic diffusion-
weighted MRI (DW-MRI) and whole-body 18F-FDG PET/CT on
the same day for initial staging, before neoadjuvant treatment. Of
27 included patients, 3 patients were classified as T3 stage by
ERUS, but downstaged to T2 stage after MRI. Because of the dis-
crepancy between ERUS and MRI, these 3 patients were excluded.
Twenty-four patients were thus included in the statistical analysis.
The institutional review board has approved the study, and
written informed consent was obtained from all patients before in-
clusion in the study.
MRI Protocol
MRI examinations were performed on a 1.5-T scanner
(Magnetom Aera; Siemens Healthcare, Erlangen Germany) usingwww.nuclearmed.com 289
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with the patient in a supine position on the MR table. No rectal
cleansing, rectal enema, or air insufflation was performed. After
fasting for at least 6 hours before the MRI, all patients were intra-
venously injected with 20 mg of scopolamine butylbromide
(Buscopan; Boehringer Ingelheim, Basel, Switzerland) or, if con-
traindicated, with 1 mg of glucagon (Glucagen; Novo Nordisk,
Bagsvaerd, Denmark) to reduce artifacts due to bowel peristalsis.
MRI protocol parameters were the same for all patients (Table 1).
Three-plane (axial, sagittal, and coronal) T2-weighted turbo spin
echo (TSE) images of the rectum were first obtained with an axial
acquisition perpendicular to the rectal tumor. Axial T2-weighted
TSE images of the upper pelvis including the iliac bifurcation were
also acquired. Axial single-shot spin-echo echo-planar DWI se-
quences in 3 orthogonal directions (frequency encoding, phase
encoding, and slice encoding) with 2 b values = 0 and 600 s/mm2
were subsequently acquired from the iliac bifurcation to the anal
verge. Pixel-to-pixel ADC maps were generated from DWI using
Siemens software.
18F-FDG PET/CT Protocol
All PET/CT examinations were performed on a Discovery
690 PET/CT scanner (GE Healthcare, Milwaukee, Wis). After
fasting for at least 6 hours before the examination, patients were
intravenously injected with 248 ± 43 MBq (range, 160–374 MBq)
of 18F-FDG. Blood glucose level was checked to be less than
8.3 mmol/L prior to administering 18F-FDG. A vertex-to-midthigh
PET/CT acquisition (time-of-flight 3D mode; 7–9 steps of
2 minutes; mean duration, 16 ± 1 minutes; range, 14–18 minutes)
was performed 66 ± 6 minutes (range, 55–76 minutes) after
18F-FDG administration. Step duration was not adjusted according
to patient body mass index. It was preceded by an unenhanced
MDCT (64-row detector, 120 kV, automatic tube intensity modula-
tion, pitch 1.5, 0.5-second rotation time, 3.75-mm slice thickness)
used for attenuation correction. PET data were reconstructed using
an ordered-subset expectation maximization method with 8 subsets
and 2 iterations.
PET/CT and MR Images Analysis
Two readers, one with 4 years of experience as a radiologist
and the other with 8 years of experience as both a radiologist and
a nuclear physician, blinded to ERUS and colonoscopic results, re-
viewed the MR and PET/CT examinations on a PACS workstationTABLE 1. Pulse Sequence Parameters
Parameters
Sagittal T2-Weighted
TSE of the Rectum
Axial T2-Weighted
Perpendicular to
Rectal Tumor
Matrix size 384  384 320  320
Slice thickness, mm 4 3
Distance factor, % 20 20
Repetition time, ms 4000 6370
Echo time, ms 103 99
Echo trains per slice (1) 8 11
Flip angle, degrees 160 160
Average 3 3
FoV, mm 180  289 180  289
Bandwidth, Hz/pixel 200 200
Acquisition time 3 min 22 s 3 min 38 s
(1) indicates means the number of echos per echo train and is a free variable (without
290 www.nuclearmed.com(CARESTREAM PACS Client, version 11; Carestream Health,
Rochester, NY) in consensus.
Rectal Cancer Analysis
For all tumors, the stage revealed by MRI (T3 or T4), the
location within the rectum (lower, middle, or upper third), the dis-
tance to the anal verge in millimeters, the longitudinal extension
of the tumor in millimeters, the presence (scored as follows: 0 if
absent or 1 if present), and location (anterior, posterior, or lateral
rectal walls) of spicules 3 mm or greater within the mesorectal fat
were recorded.
The highest 18F-FDG SUV was automatically detected.
Then, in consensus, the 2 readers drew ellipsoid ROIs of 1 cm2 on
the tumor area of the rectal wall containing the highest 18F-FDG
SUV on axial PET images and measured the SUVmax and
SUVmean of the rectal cancer (Fig. 1).
After spatial rigid coregistration of the DWI with the
18F-FDG PET/CT images, the same ROI was automatically trans-
ferred onto the ADC map generated from DWI. The ADCmin and
ADCmean were then measured.
Regional Lymph Nodes Analysis
No pathological specimen was available in our untreated
population, because all patients immediately underwent neoad-
juvant radiochemotherapy after imaging. Therefore, for regional
lymph node analysis, the combination of 18F-FDG PET/CT and
morphological MRI criteria was considered as the standard of refer-
ence.13 Lymph nodes were defined as pathological when demon-
strating a short axis of 6 mm or greater, round shape, loss of fatty
hilum, indistinct borders, heterogeneous signal on T2-weighted
MR images,5 and an 18F-FDG uptake higher than the background
activity of soft tissues on PET/CT images. For comparison, the
2 readers also evaluated control lymph nodes that were defined
as having a short axis of 6 mm or greater, oval shape, preserved
fatty hilum, smooth borders, homogeneous signal on T2-weighted
MR images, and an 18F-FDG uptake lower than the background
activity of soft tissues on PET/CT-images. All the chosen con-
trol lymph nodes were located in the inguinal chain of patients
who did not have any external iliac or inguinal pathological
lymph nodes. For both pathological regional lymph nodes and
control lymph nodes, ROIs (size range, 0.3–1 cm2) were drawn in
consensus around the nodes, and SUVmax and SUVmean values
were measured.TSE
the
Oblique Coronal
T2-Weighted TSE
of the Rectum
Axial T2-Weighted
TSE of the
Upper Pelvis
Diffusion
Weight
320  320 320  320 160  160
3 3 5
20 20 10
4000 4000 3200
99 103 55
11 11
160 160
3 2 6
180  289 220  354 350  563
200 200 148
4 min 34 s 3 min 6 s 1 min 34 s
units) in the international system; FoV, field of view.
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FIGURE 1. Locally advanced rectal cancer in a 50-year-old man. A, Axial T2-weighted MR image shows a T4-stage rectal
tumor with predominant thickening of the right wall. B, Axial 18F-FDG PET/CT demonstrates high tumor 18F-FDG uptake
(SUVmean = 10.5 g/mL, SUVmax = 14.7 g/mL). C and D, Axial diffusion-weighted image and ADC map show diffusion
restriction within the tumor (ADCmean = 953  10−6 mm2/s, ADCmin = 882  10−6 mm2/s).
Clinical Nuclear Medicine • Volume 41, Number 4, April 2016 DW-MRI in LARCTheADCmin andADCmeanvalues of the lymph nodes were
again measured by applying the same ROI on ADC maps after
coregistration with 18F-FDG PET/CT images (Fig. 2). The number,
location, and size of all the pathological and control lymph nodes
were also recorded.Statistical Analysis
Datawere analyzed using Stata 13.1 software (Stata Corpora-
tion, College Station, Tex). Continuous variables are presented as
mean ± SD, and categorical variables as number or percentage.
The nonparametric Kruskal-Wallis test was used to compare
SUVmax, SUVmean, ADCmin, and ADCmean between tumor
subgroups. The same test was used to compare the size, SUVmax,
SUVmean, ADCmin, and ADCmean of pathological versus con-
trol lymph nodes. We assessed the relations between SUVmax,
SUVmean, ADCmin, and ADCmean of the rectal tumors and of
the lymph nodes by computing the Spearman ρ correlation coeffi-
cient. Values of Spearman ρ values were interpreted as follows:
0 or less was poor, 0 to 0.20 was slight, 0.21 to 0.40 was fair,
0.41 to 0.60 was moderate, 0.61 to 0.80 was substantial, and 0.8
to 1 was good to very good. ROC analysis with determination of
the AUC and a corresponding 95% confidence interval (95% CI)
was performed to evaluate ADCmean and ADCmin diagnostic© 2016 Wolters Kluwer Health, Inc. All rights reserved.values for lymph node characterization. P < 0.05 was considered
statistically significant.
RESULTS
Patients’ Characteristics
Twenty-four patients with untreated LARC were included in
the statistical analysis (18 men, 6 women; mean age, 64 ± 12 years
[range, 45–87 years]). Twenty patients (83%) had a T3 stage tumor,
and 4 patients (17%) had a T4 stage tumor, which were all histolog-
ically characterized as rectal adenocarcinoma. Of the 24 tumors, 4
were located in the lower third, 13 in the middle third, and 7 in the
upper third of the rectum. The mean distance from the tumor to
the anal verge was 67 ± 27 mm, and the mean longitudinal exten-
sion was 54 ± 25 mm. Twenty-two tumors displayed spicules in
the mesorectal fat, among which 10 along the anterior wall, 6 along
the posterior wall, and 10 along the lateral walls of the rectum.
Rectal Cancer Results
SUVmax and SUVmean values of the rectal cancers (n = 24)
were 17.5 ± 8.2 and 13.3 ± 6.1 g/mL, respectively, whereas their
ADCmin and ADCmean values were 787 ± 185  10−6 mm2/s
and 1057 ± 218  10−6 mm2/s, respectively. There was no statisti-
cally significant difference of SUVmax, SUVmean, ADCmin, orwww.nuclearmed.com 291
FIGURE 2. Pathological lymph node in a 69-year-old man with a T4 N2 stage rectal cancer. A, Axial T2-weighted MR
image shows a pathological lymph node located in the posterior mesorectum. B, Axial 18F-FDG PET/CT demonstrates high
18F-FDG uptake of this same lymph node (SUVmean = 8.9 g/mL, SUVmax = 10.7 g/mL). C and D, Axial diffusion-weighted
image and ADC map show a focal diffusion restriction within the lymph node (ADCmean = 1047  10−6 mm2/s,
ADCmin = 763  10−6 mm2/s).
Cerny et al Clinical Nuclear Medicine • Volume 41, Number 4, April 2016ADCmean between T3 and T4 tumors (P > 0.19). The difference of
SUVmax, SUVmean, ADCmin, or ADCmean was not statistically
significant for tumors in different rectal locations or the presence
of spicules (P > 0.14, Table 2).
As for the rectal cancer, we found a substantial significant
negative correlation between the SUVmean and the corresponding
ADCmean values (ρ = −0.61, P = 0.0017) (Fig. 3) and betweenTABLE 2. Rectal Tumors SUV and ADC Values
Tumors n SUVmean, g/mL P SUVmax, g/mL
All 24 13.3 ± 6.1 17.5 ± 8.2
Stage
T3 20 12.5 ± 5.7 0.22 16.3 ± 7.5
T4 4 17.6 ± 6.7 23.6 ± 10.2
Location
Low rectum 4 15.6 ± 9.1 0.8 22.6 ± 12.6
Mid rectum 13 13.1 ± 6.0 17.2 ± 8.0
High rectum 7 12.4 ± 4.9 15.1 ± 5.4
Spicules
Present 22 13.5 ± 6.3 0.83 17.7 ± 8.6
Absent 2 11.3 ± 1.1 15.3 ± 0.8
292 www.nuclearmed.comADCmin and SUVmax values (ρ = −0.66, P = 0.0005). SUVmax,
SUVmean, ADCmin, and ADCmean were not significantly corre-
lated with longitudinal tumor extension (P > 0.08).
Regional Lymph Node Results
In total, 44 pathological and 19 control lymph nodes were
evaluated. Among the 44 pathological regional lymph nodes weP ADCmean, 10−6 mm2/s P ADCmin P
1057 ± 218 787 ± 185
0.19 1080 ± 228 0.28 799 ± 200 0.64
942 ± 115 726 ± 53
0.8 1108 ± 250 0.92 898 ± 300 0.36
1058 ± 242 744 ± 183
1024 ± 175 804 ± 83
1.0 1070 ± 223 0.14 792 ± 187 0.83
914 ± 56 733 ± 211
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. Correlation (ρ = −0.61, P = 0.0017) between
ADCmean and SUVmean of the rectal tumor
before treatment.
Clinical Nuclear Medicine • Volume 41, Number 4, April 2016 DW-MRI in LARChad assessed, there were 33 perirectal, 6 internal iliac, 3 external
iliac, 1 common iliac, and 1 inguinal lymph nodes. The size of path-
ological and control lymph nodes was not significantly different
(8.3 ± 3.7 vs 7.2 ± 1.4 mm, P = 0.41). The mean SUVmax and
SUVmean were significantly higher in the pathological lymph
nodes than in the control lymph nodes (7.0 ± 5.4 vs 1.3 ± 0.5 g/mL
and 5.0 ± 3.7 vs 1.0 ± 0.4 g/mL, P = 0.0001). This was the case
for pathological lymph nodes equal to or smaller than 1 cm
(n = 38, P = 0.0003) or larger than 1 cm (n = 6, P = 0.0001).
ADCmean was significantly lower in pathological lymph nodes
(1099 ± 185 vs 1379 ± 324 10−6 mm2/s, P = 0.0012) than in con-
trol lymph nodes. This was the case for pathological lymph nodes
equal to or smaller than 1 cm (n = 38, P = 0.003) or larger than
1 cm (n = 6,P = 0.009). ADCminwas not significantly different be-
tween pathological and control lymph nodes (821 ± 214 vs
890 ± 400 10−6 mm2/s, P = 0.27). This was the case for patholog-
ical lymph nodes equal to or smaller than 1 cm (n = 38, P = 0.38) or
larger than 1 cm (n = 6, P = 0.16).
Taking into account all pathological and control lymph
nodes (n = 63), ADCmean showed a fair but statistically significant
negative correlation with the corresponding SUVmean values
(ρ = −0.38, P = 0.0021). There was, however, no statistically signif-
icant correlation between ADCmin and SUV max (ρ = −0.11,
P = 0.41). SUVmean and SUVmax values were statistically signif-
icantly correlated with lymph node size (ρ = 0.42, P < 0.0007), but
there was no statistically significant correlation between lymph
node size and ADC mean (ρ = −0.08, P = 0.54) or ADCmin
(ρ = −0.06, P = 0.62) values.
With AUCs of 0.24 (95% CI, 0.10–0.38) and 0.41 (95% CI,
0.22–0.60), respectively, neither ADCmean nor ADCmin values
allowed for accurate distinction between pathological and control
lymph nodes when compared with the combination of morpholog-
ical MRI and PET/CT criteria.© 2016 Wolters Kluwer Health, Inc. All rights reserved.DISCUSSION
PET/CT and DW-MRI are 2 complementary modalities used
for initial staging in primary rectal cancer, providing information
about metabolic activity and cellularity. Both modalities provide in-
formation about tumor features and have been shown to be useful in
evaluating tumor response to treatment.14–17
The purposes of this study were to assess the relation be-
tween quantitative parameters resulting from DW-MRI and 18F-FDG
PET/CT imaging of regional lymph nodes in untreated LARC and
the associated primary tumor, as well as to determine the diagnos-
tic performance of ADC values in identifying pathological lymph
nodes. We found a statistically significant correlation between
ADCmean and SUVmean for the regional lymph nodes and the rec-
tal tumor. To the best of our knowledge, our study is the first that
confirms an association between the tumor cellularity and the met-
abolic activity both in pathological lymph nodes and the related un-
treated LARC.11,12 ADCmin and ADCmean did not, however, help
differentiate pathological from benign lymph nodes.
In rectal cancer, the correct initial local staging is important
for distinguishing between locally advanced tumors (T3 and T4)
and less invasive tumors (T1 and T2) when choosing the optimal
treatment (surgery, neoadjuvant chemoradiotherapy, radiotherapy,
or chemotherapy alone). As the neoplastic specimen (primary tu-
mor or lymph node) is not available for histological examination
prior to treatment, imaging is of paramount importance. Endorectal
US, CT, andMRI have been widely used for rectal cancer staging.18
As to MRI, field strengths of either 3 T or 1.5 T may be used.19 In-
deed, a direct comparison20 could not reveal any improved accuracy
in T staging of rectal cancer when using 3-T MR scanners despite
their 2-fold increase in the signal-to-noise ratio compared with
1.5-T MR machines.
Because most primary rectal tumors show intense 18F-FDG
uptake,6 18F-FDG PET/CT has also emerged as a promising option
for the staging of LARC. It can correctly identify 94.6% of rectal
adenocarcinomas and define their local extension (T stage) with
an accuracy of 94.3% (95% CI, 87%–100%).21 Only a few studies
have reported a comparison between the SUV uptake of 18F-FDG
PET/CT and the ADC values generated from DWI for the initial
quantitative assessment of primary rectal tumors. In our study,
we did not find any statistically significant difference of tumor
SUVmax, SUVmean, ADCmin, or ADCmean for tumors with dif-
ferent T stages or locations within the rectum. Curvo-Semedo et al8
showed that lower ADCmean values are associated with a more ag-
gressive tumor profile and are significantly correlated with the
mesorectal fascia extension seen on MRI and with their grade of
differentiation. To the contrary, we found neither any statistically
significant difference of tumor SUV or ADC with respect to the
presence or absence of perirectal spicules, nor any relation between
SUV or ADC and longitudinal tumor extension. This suggests, as
previously reported by Uchiyama et al,22 that the primary tumor
morphology may not necessarily be related to metabolism or cellu-
larity. However, we found a statistically significant negative correla-
tion between ADCmean and the corresponding SUVmean values
(ρ = −0.61, P = 0.0017) and between ADCmin and SUVmax
(ρ = −0.66, P = 0.0005) values. Two previous studies11,12 have
shown a significant negative correlation between ADCmin and
SUVmax (r = −0.450, P = 0.009; and r = −0.347, P = 0.026, re-
spectively) for primary rectal adenocarcinoma. In these studies,
ADCmin was determined as the lowest value and SUVmax as the
highest value among all voxels of the entire volume in each tumor.
However, there was no certitude that the tumor area with the maxi-
mum SUV value corresponded to the tumor area with the minimum
ADC value.11,12 Unlike these authors, we spatially coregistered our
DWI with 18F-FDG PET/CT images after drawing a 1-cm2 ROIwww.nuclearmed.com 293
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termine SUVmax. Thus, we aimed at obtaining a perfect anatomic
correlation for the 2 imaging modalities in order to be able to com-
pare SUVmax and ADCmin values as true comparables. With the
same rigid anatomic coregistration, we similarly assessed the rela-
tion between SUVmean and ADCmean values, which may explain
the stronger correlation (ρ = −0.61, P = 0.0017) compared with the
values reported by Gu et al11 (r = −0.402, P = 0.02).
The exact staging of regional lymph node status is also man-
datory for determining the optimal therapy. Size, shape, delineation,
and texture of lymph nodes are morphological criteria used for
characterization, but none has proven to be a sufficient criterion.5
In concordance with Monig et al, who found that size is not a good
criterion for differentiating metastatic from disease-free lymph
nodes,23 we did not find any statistically significant difference in
size between pathological and control lymph nodes. For the detec-
tion of malignant lymph nodes, PET/CT has a sensitivity of 61%,
with a high specificity of 83%, whereas MRI has a high sensitivity
of 94%, but a specificity of only 67%.13 Combining high-resolution
pelvic MRI and 18F-FDG PET/CT improves the accuracy of nodal
status prediction.13 Diffusion-weighted imaging can also facilitate
lymph node detection better than T2-weighted MR sequences
can, but without being reliable for differentiating between benign
and malignant lymph nodes (AUC = 0.45–0.64).24,25 Evaluating
196 histologically benign and 16 histologically malignant lymph
nodes, Heijnen et al24 also reported that the ADCmean value
was higher for benign lymph nodes (1.150 ± 0.24 vs 1.04 ± 0.22 
10−3 mm2/s), although not statistically significant (P = 0.10), prob-
ably because of insufficient reproducibility of ADC measure-
ment in the lymph nodes.26 We hereby confirm and extend
these results by demonstrating that the ADCmean, but not the
ADCmin value, was lower in pathological regional lymph nodes,
regardless of pathological lymph node size. With an AUC of
less than 0.50 on ROC analysis, ADC values were, however,
not reliable for accurately distinguishing between pathological
and benign lymph nodes at initial staging. To the best of our
knowledge, only Cho et al27 reported that ADC values help iden-
tify metastatic lymph nodes using radiological-pathological
correlation of all lymph nodes greater than 2 mm in surgical speci-
mens in patients with rectal cancer. Some concerns regarding the
methodology may explain the nonreproducibility of these results.
First, the difference in size between benign and malignant nodes
(3.5 ± 1.6 vs 6.4 ± 3.3 mm, P < 0.0001) could have influenced
the ADC values because of background noise, although interob-
server agreement was good. Second, the exact spatial correlation
of lymph nodes with a diameter of less than 5 mm between DWI
andmacroscopic surgical specimens may be questionable regarding
tissues shrinking after resection, as indirectly confirmed by the high
exclusion rate of lymph nodes in this study (354/468 = 76%).While
ADC values did not identify pathological lymph nodes, a signifi-
cant negative correlation between SUVmean and ADCmean of
the lymph nodes was found, suggesting an association between me-
tabolism and cellularity of the primary rectal tumor, similarly to
other cancers.9,28
Hybrid FDG PET/MRI has been reported as an evolving tool
for the workup of advanced rectal cancer,29,30 thus combining the
excellent soft tissue contrast of MRI and the high sensitivity for N
and M staging inherent in PET. Preliminary results suggest that
PET/MRI allows for more detailed T staging than PET/CT,29 but
the accuracy in N staging does not seem to change significantly,
when compared with PET/CT.29,30
We have to address some limitations of our study. First,
no histopathologic analysis of our included lymph nodes was avail-
able. Becausewe included only LARC, all our patients immediately
underwent neoadjuvant radiochemotherapy after initial staging and294 www.nuclearmed.combefore surgery. Because of morphological changes induced by the
neoadjuvant therapy, histological analysis could not be used as the
standard of reference in these settings. However, using automatic
coregistration software, we obtained perfect anatomic correlation
for measuring 18F-FDG PET/CT and DWI quantitative parameters
in both tumors and lymph nodes when compared with previously
published studies using these methods. Second, 18F-FDG PET/CT
examination was performed on a Discovery 690 PET/CT scanner
(GE Healthcare, Milwaukee, Wis). Owing to a transverse spatial
resolution (4.7 mm) higher than that of PET scanners used in previ-
ous studies (6.7–9 mm),12,21 SUVmax and SUVmean values may
be significantly increased for small lesions such as lymph nodes be-
cause of partial volume effect reduction, thus limiting the possibility
of comparing the studies.
In conclusion, we report a statistically significant nega-
tive correlation between ADCmean and SUVmean values both in
primary LARC and regional lymph nodes in the same patient
population, thus confirming an association between tumor cellular-
ity and metabolic activity. ADC values were, however, unreliable
for purposes of distinguishing between pathological and normal
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